+

WO2002018630A3 - Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien - Google Patents

Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien Download PDF

Info

Publication number
WO2002018630A3
WO2002018630A3 PCT/DE2001/003323 DE0103323W WO0218630A3 WO 2002018630 A3 WO2002018630 A3 WO 2002018630A3 DE 0103323 W DE0103323 W DE 0103323W WO 0218630 A3 WO0218630 A3 WO 0218630A3
Authority
WO
WIPO (PCT)
Prior art keywords
resistances
resistance profiles
tissues
cell lines
vis
Prior art date
Application number
PCT/DE2001/003323
Other languages
English (en)
French (fr)
Other versions
WO2002018630A2 (de
Inventor
Ulrike Stein
Peter Michael Schlag
Original Assignee
Max Delbrueck Centrum
Ulrike Stein
Peter Michael Schlag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Ulrike Stein, Peter Michael Schlag filed Critical Max Delbrueck Centrum
Priority to EP01980157A priority Critical patent/EP1315838A2/de
Priority to US10/415,491 priority patent/US20040058352A1/en
Publication of WO2002018630A2 publication Critical patent/WO2002018630A2/de
Publication of WO2002018630A3 publication Critical patent/WO2002018630A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die Effizienz einer Chemotherapie maligner Erkrankungen ist oft durch Resistenzen gegenüber der eingesetzten Zytostatika limitiert, die durch eine Vielzahl unterschiedlicher, parallel oder sequentiell auftretender Mechanismen vermittelt werden. Gegenstand der Erfindung ist die Verwendung eines Verfahrens zur Erfassung von Resistenz-Profilen mittels RNA aus Geweben bzw. Zelllinien mit der real time-RT-PCR-Technologie (durchführbar z.B. am Light Cycler, Roche Diagnostics GmbH). Es können so die Expressionen unterschiedlicher Gene, die an der Entstehung oder Verstärkung oder Verminderung von Resistenzen beteiligt sind, quantitativ nachgewiesen werden. Basierend darauf können dann z.B. Patienten-individuelle Resistenz-Profile erstellt werden, die die molekularbiologische Grundlage zur Auswahl geeigneter Zytostatika vor und auch während der jeweiligen Tumorchemotherapie bilden. Darüber hinaus können prognostisch die Erfolgschancen (Response) bestimmter chemotherapeutischer Regime abgeschätzt werden.
PCT/DE2001/003323 2000-09-01 2001-09-03 Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien WO2002018630A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01980157A EP1315838A2 (de) 2000-09-01 2001-09-03 Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien
US10/415,491 US20040058352A1 (en) 2000-09-01 2001-09-03 Method of establishing resistance profiles of tissues and cell lines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043591A DE10043591A1 (de) 2000-09-01 2000-09-01 Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
DE10043591.2 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002018630A2 WO2002018630A2 (de) 2002-03-07
WO2002018630A3 true WO2002018630A3 (de) 2002-11-21

Family

ID=7654966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/003323 WO2002018630A2 (de) 2000-09-01 2001-09-03 Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien

Country Status (4)

Country Link
US (1) US20040058352A1 (de)
EP (1) EP1315838A2 (de)
DE (1) DE10043591A1 (de)
WO (1) WO2002018630A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126272A1 (en) * 2002-08-28 2004-07-01 Eric Bornstein Near infrared microbial elimination laser system
US20040156743A1 (en) * 2002-08-28 2004-08-12 Eric Bornstein Near infrared microbial elimination laser system
US7713294B2 (en) 2002-08-28 2010-05-11 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser systems (NIMEL)
US7470124B2 (en) * 2003-05-08 2008-12-30 Nomir Medical Technologies, Inc. Instrument for delivery of optical energy to the dental root canal system for hidden bacterial and live biofilm thermolysis
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
WO2005078100A1 (ja) * 2004-02-13 2005-08-25 Bml, Inc. 薬剤耐性を獲得した癌細胞の検出方法
AU2006272766A1 (en) * 2005-07-21 2007-02-01 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser system (NIMELS)
EP1946114A4 (de) * 2005-09-21 2010-05-26 Ccc Diagnostics Llc Umfassende diagnostische testverfahren zur persönlichen antikrebs-chemotherapie (pac)
BRPI0711011A2 (pt) * 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN106153918A (zh) * 2008-10-14 2016-11-23 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
WO2010093465A1 (en) * 2009-02-11 2010-08-19 Caris Mpi, Inc. Molecular profiling of tumors
DE102017110966A1 (de) 2017-05-19 2018-11-22 Renk Aktiengesellschaft Getriebe insbesondere für Windkraftgeneratoren

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832653A1 (de) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832653A1 (de) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FANEYTE I F ET AL.: "Determining MDR1/P-glycoprotein expression in breast cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 93, July 2001 (2001-07-01), pages 114 - 122, XP002210331 *
FUNATO, T. ET AL.: "Genetic diagnosis for drug resistance in cancer", RINSHO BYORI. JAPANESE JOURNAL OF CLINICAL PATHOLOGY, vol. 48, February 2000 (2000-02-01), pages 162 - 166, XP008006762 *
NOONAN K E ET AL: "QUANTITATIVE ANALYSIS OF MDR1 (MULTIDRUG RESISTANCE) GENE EXPRESSION IN HUMAN TUMORS BY POLYMERASE CHAIN REACTION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 18, 1 September 1990 (1990-09-01), pages 7160 - 7164, XP000351423, ISSN: 0027-8424 *
SCHIEDLMEIER B ET AL.: "Human multidrug resistance-1 gene transfer to long-term repopulating human mobilized peripheral blood progenitor cells", BONE MARROW TRANSPLANTATION, vol. 25, no. Sup2, May 2000 (2000-05-01), pages S118 - S124, XP008006761 *
STEIN U ET AL: "MODULATION OF MDR1 EXPRESSION BY CYTOKINES IN HUMAN COLON CARCINOMA CELLS: AN APPROACH FOR REVERSAL OF MULTIDRUG RESISTANCE", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 74, no. 9, 1 November 1996 (1996-11-01), pages 1384 - 1391, XP000645159, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
DE10043591A1 (de) 2002-03-14
US20040058352A1 (en) 2004-03-25
EP1315838A2 (de) 2003-06-04
WO2002018630A2 (de) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2002018630A3 (de) Verfahren zur erfassung von resistenz-profilen von geweben und zelllinien
AU740708B2 (en) Improved cycle sequencing thermal profiles
JP2021073252A5 (de)
Myrick et al. Universal fast walking for direct and versatile determination of flanking sequence
CA2239287A1 (en) A cascade nucleic acid amplification reaction
WO2004092418A3 (en) Global amplification using a randomly primed composite primer
CN106148521B (zh) 一种多点突变单管快速检测方法及试剂盒
DE69225074D1 (de) Verfahren zur vorbereitung von doppel strangiger rna und seine anwendungen
CA2167838A1 (en) Methods for Enhancing Nucleic Acid Amplification
DE69626111D1 (de) Universale primersequenz zur multiplex dna amplifikation
CA2435917A1 (en) Highly sensitive method for the detection of cytosine methylation patterns
EP1572964A4 (de) Doppelsträngige rna-strukturen und konstrukte sowie verfahren zur erzeugung und verwendung davon
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2019075251A3 (en) Cancer score for assessment and response prediction from biological fluids
EP1212449A4 (de) Verfahren zur amplifikation von signal-flankierenden sequenzen aus unbekannten, genomischen daten
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
PT1171634E (pt) Pares de iniciadores de amplificacao e de sequenciacao e sua utilizacao
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
KR20180125058A (ko) 탈모 예측용 snp 프라이머 및 이의 용도
CN111681711A (zh) 一种兼并引物的设计筛选方法
EP1405923A3 (de) Verahren zur Genkartierung durch die Verwendung von polymorphischen Mikrosatellitenmarkers
WO2006018290A3 (de) Verfahren und kit zur diagnose einer krebserkrankung verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung
US20070299255A1 (en) Compositions and Methods for Amplification and Cloning of Near Full-Length Viral Genome Samples
EP1634959A3 (de) Methode zur Bereitstellung von Proben und Mikroarrays, deren Verwendung und ein Computerprogramm für die Herstellung der Proben
WO2003018837A3 (de) Verfahren und diagnosekit zur molekularen diagnostik pharmakologisch relevanter gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001980157

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10415491

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001980157

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载